Literature DB >> 7130169

Purification and properties of feline and human arylsulfatase B isozymes. Evidence for feline homodimeric and human monomeric structures.

M M McGovern, D T Vine, M E Haskins, R J Desnick.   

Abstract

Normal feline and human arylsulfatase B isozymes were purified to homogeniety from liver. The specific activities of the feline and human enzymes toward p-nitrocatechol sulfate were 1,100,000 and 800,000 units/mg of protein, and toward UDP-N-acetylgalactosamine-4-sulfate were 5,500 and 4,000 units/mg of protein, respectively. Although both enzymes had the same pH optimum (5.7), the feline enzyme was more electronegative than the human enzyme when electrophoresed on polyacrylamide gels. Compared to the human isozyme, feline arylsulfatase B had a lower Km toward p-nitrocatechol sulfate (1.2 versus 3.6 mM), was more thermostable at 60 degrees C (68 versus 30 min), and had a slightly lower pI (7.8 versus 8.0). The native molecular weight of the feline enzyme was estimated to be about twice that the human isozyme by gel filtration, analytical polyacrylamide gel electrophoresis, and sucrose density-gradient centrifugation. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis revealed single protein bands of Mr = 41,000 and 38,000 for the feline and human isozymes, respectively. Alkylation and cross-linking experiments were consistent with the feline enzyme being a homodimer and the human enzyme a monomer. Amino acid compositional analyses revealed few significant differences between the two isozymes.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7130169

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

Review 1.  Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives.

Authors:  Melani Solomon; Silvia Muro
Journal:  Adv Drug Deliv Rev       Date:  2017-05-11       Impact factor: 15.470

2.  Animal models for lysosomal storage diseases: a new case of feline mucopolysaccharidosis VI.

Authors:  P Di Natale; T Annella; A Daniele; G Spagnuolo; R Cerundolo; D de Caprariis; A E Gravino
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

3.  Mammalian arylsulfatases A and B: relative rates of hydrolysis of artificial substrates.

Authors:  D B Thompson; W L Daniel
Journal:  Experientia       Date:  1986-02-15

4.  Enzyme replacement therapy in a feline model of Maroteaux-Lamy syndrome.

Authors:  A C Crawley; D A Brooks; V J Muller; B A Petersen; E L Isaac; J Bielicki; B M King; C D Boulter; A J Moore; N L Fazzalari; D S Anson; S Byers; J J Hopwood
Journal:  J Clin Invest       Date:  1996-04-15       Impact factor: 14.808

5.  Comparison of arylsulphatases from Eimeria tenella (parasite) and chicken caecum (host).

Authors:  A A Farooqui; W L Hanson
Journal:  Biochem J       Date:  1987-02-15       Impact factor: 3.857

6.  Animal model studies of allelism: characterization of arylsulfatase B mutations in homoallelic and heteroallelic (genetic compound) homozygotes with feline mucopolysaccharidosis VI.

Authors:  M M McGovern; N Mandell; M Haskins; R J Desnick
Journal:  Genetics       Date:  1985-08       Impact factor: 4.562

7.  Human N-acetylgalactosamine-4-sulphate sulphatase. Purification, monoclonal antibody production and native and subunit Mr values.

Authors:  G J Gibson; G T Saccone; D A Brooks; P R Clements; J J Hopwood
Journal:  Biochem J       Date:  1987-12-15       Impact factor: 3.857

8.  Mucopolysaccharidosis type I subtypes. Presence of immunologically cross-reactive material and in vitro enhancement of the residual alpha-L-iduronidase activities.

Authors:  E H Schuchman; R J Desnick
Journal:  J Clin Invest       Date:  1988-01       Impact factor: 14.808

Review 9.  Mucopolysaccharidosis type VI (MPS VI) and molecular analysis: Review and classification of published variants in the ARSB gene.

Authors:  Rosella Tomanin; Litsa Karageorgos; Alessandra Zanetti; Moeenaldeen Al-Sayed; Mitch Bailey; Nicole Miller; Hitoshi Sakuraba; John J Hopwood
Journal:  Hum Mutat       Date:  2018-09-17       Impact factor: 4.878

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.